# Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00310024** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** vorinostat
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00310024
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310024, "Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00310024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*